We produce and develop drugs and vaccines that big pharmaceutical companies are not interested in due to their lack of a commercial market so that these products can be stockpiled and be made available in an emergency situation.

Established in 2018, Global Urgent and Advanced Research and Development (GUARD) executes pre-clinical and clinical development strategies on prophylactic and therapeutic products for neglected emerging infectious diseases.

A main objective is to accumulate clinical data packages within rigorous regulatory processes to support further clinical progression during outbreaks and contribute to global stockpiles and security.

GuardRX envisions becoming a global resource for the clinical development and stockpiling of these products by:

  • Acquiring licenses for products in advanced stages of pre-clinical development that would otherwise not enter the clinic;
  • Establishing connections with funding agencies, CMOs, CROs, and global stockpile institutions; and,
  • Delivering products with initial clinical data packages developed with rationalized resource investment in order to optimize the response to emergencies of public health concern.